Nuvera Biosciences Licenses PGx Assays to Veridex

The assays that Veridex will commercialize were developed to predict patient response to tamoxifen therapy and taxane-containing chemotherapy in breast cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories